A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections

Table 3 Logistic regression analysis of the factors related to HBV VBIs

	Univariate		Multivariate^a
	OR (95% CI)	P	Adjusted OR (95% CI)	P
Mothers
HBeAg (Positivity vs. Negativity)	4.79 (2.19–10.45)	< 0.001	4.43 (1.94–10.12)	< 0.001
HBV DNA level (per log₁₀ IU/mL increase)	1.31 (1.14–1.50)	< 0.001	1.30 (1.13–1.51)	< 0.001
HBsAg level (per log₁₀ IU/mL increase)	2.06 (1.23–3.45)	0.006	2.09 (1.20–3.62)	0.009
Age (per 1-year increase)	0.96 (0.88–1.03)	0.247
HBV genotype (C vs. B)	1.05 (0.30–3.70)	0.937
Infants
Initial anti-HBs level (per log₁₀ mIU/mL increase)	0.43 (0.23–0.79)	0.006	0.27 (0.13–0.55)	< 0.001
Parturition manner (Caesarean vs. Vaginal)	0.50 (0.24–1.04)	0.062
Feeding pattern (Breast vs. Artificial)	1.28 (0.61–2.67)	0.521
Booster HepB (no vs. yes)	27.16 (3.67–201.00)	0.001	35.52 (4.65–271.57)	0.001

^aMaternal HBeAg status, HBV DNA levels and HBsAg levels were analysed separately in three models

ISSN: 1471-2334